We showed that the percent change of ACR from baseline to the final visit was approximately 30 % with time-dependent manner in topiroxostat group compared to placebo group. In addition, topiroxostat did not show the clear effect on either the change of blood pressure or the change of eGFR. The reported correlation between allopurinol and reduction of albuminuria is controversial.

While one clinical study of this website allopurinol in patients with CKD suggested that allopurinol could have a potency to decrease albuminuria, another study reported no effect on albuminuria [10, 11]. On the other side, the finding of ACR-lowering effect by topiroxostat in this study is consistent with the findings Erastin manufacturer of experimental studies of other xanthine oxidase inhibitors [24, 25]. In this study, we did not prohibit concomitant use of blood-pressure-lowering agents, including ACE inhibitors, ARBs, aldosterone blockers or renin inhibitors (RAA blockers). Also, it was not necessary for the patients to take

maximal doses of the RAA blockers. Therefore, these results might have been affected by the different classes or doses of these drugs used concomitantly. To verify the robustness of the ACR-lowering effect of topiroxostat, we confirmed similar ACR-lowering effect in the other data set (per protocol set) in which the data of ACR after the time point were excluded if patients changed the type or dose of their blood-pressure-lowering agent during the study. Also, we considered the possible dependence of the degree of ACR reduction on the initial value.

However, no relationship could be demonstrated between the baseline ACR and the change in the ACR in either group. In addition, the serum albumin levels in both groups remained stable during Resveratrol the study (data not shown). The incidence of total AE was similar in both groups. The incidence of ‘ALT increased’ was statistically significantly higher in the topiroxostat group as compared with that in the placebo group. However, the frequency of concurrent increase of the ALT with the total bilirubin or alkaline phosphatase was similar in both groups. In this study, we excluded patients with selleck chemicals hepatic dysfunction in exclusion criteria. Therefore, it will be important for physicians to monitor the liver function in clinical practice. The incidences of gouty arthritis or arthralgia were not statistically significantly different between the two groups, but tended to be higher in the topiroxostat group. In this study, we did not permit colchicine prophylaxis because of assessment of the onset of gouty arthritis in the patients. Also, the doses of topiroxostat were not increased in parallel with the level of serum urate in each subject. To minimize the incidence of gouty arthritis, anti-inflammatory prophylaxis and stepwise dose titration in accordance with the level of serum urate in each subject need to be considered.